Of particular note is the update to the recommendations on the delivery of systemic therapy. Newly approved active ingredients were integrated, and there is also a special focus on the consideration of comorbidities and special treatment situations. Other updates include the concretization of the criteria for the use of biologics and “small molecules”, but practice-relevant adjustments were also made in other sections.